ストックスクリーナーアプリを入手
8.79
0.46%
0.04
前日終値:
$8.75
開ける：
$8.69
24時間の取引高:
56,720
Relative Volume:
1.25
時価総額：
$57.80M
収益：
$43.77M
当期純損益:
$-35.04M
株価収益率:
-2.7029
EPS:
-3.2521
ネットキャッシュフロー:
$-5.51M
1週間 パフォーマンス:
+10.01%
1か月 パフォーマンス:
+7.85%
6か月 パフォーマンス:
-3.41%
1年 パフォーマンス:
-4.96%
1日の値動き範囲:
$7.82
$9.215
1週間の範囲:
$7.82
$9.215
52週間の値動き範囲:
$6.4652
$12.74
Xilio Therapeutics Inc Stock (XLO) Company Profile
Compare XLO vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
8.79 | 57.80M | 43.77M | -35.04M | -5.51M | -3.2521 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-06 | 開始されました | Leerink Partners | Outperform |
| 2022-12-21 | 開始されました | Chardan Capital Markets | Buy |
| 2022-01-10 | 開始されました | H.C. Wainwright | Buy |
| 2021-11-16 | 開始されました | Cowen | Outperform |
| 2021-11-16 | 開始されました | Guggenheim | Buy |
| 2021-11-16 | 開始されました | Morgan Stanley | Overweight |
| 2021-11-16 | 開始されました | Raymond James | Outperform |
すべてを表示
Xilio Therapeutics Inc (XLO) 最新ニュース
Xilio Therapeutics Inc (XLO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Xilio Therapeutics Inc (XLO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xilio Therapeutics Inc (XLO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Xilio Therapeutics Inc (XLO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xilio Therapeutics Inc (XLO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Xilio Therapeutics Inc (XLO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Xilio Therapeutics Inc (XLO) Institutional Confidence - TradingKey
Xilio Therapeutics Inc (XLO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
XLO Stock Price, Quote & Chart - ChartMill
Xilio Therapeutics Inc (XLO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Xilio Therapeutics Adjusts Board Structure Following Shareholder Votes - The Globe and Mail
Daniel Curran reappointed to Class III director at Xilio - TradingView
Xilio Therapeutics (XLO) director receives grant of 5,000 stock options - Stock Titan
Xilio (XLO) director receives grant of 5,000 stock options at $7.99 - Stock Titan
Xilio Therapeutics (XLO) director receives grant of 5,000 stock options at $7.99 - Stock Titan
Xilio Therapeutics (XLO) director Xu Yuan receives grant of 5,000 stock options - Stock Titan
Xilio Therapeutics (XLO) director receives 5,000 stock options at $7.99 strike - Stock Titan
Xilio Therapeutics (XLO) director granted options for 5,000 shares at $7.99 - Stock Titan
Board changes and stock plan vote at Xilio Therapeutics (NASDAQ: XLO) - Stock Titan
Top Lunai Bioworks (LNAI) Competitors 2026 - MarketBeat
Xilio Therapeutics (XLO) Edges Higher, Testing Resistance After Modest GainsGolden Cross - newsline.com
XLO Q1 2026 Earnings: Narrower Loss Surprises, Clinical Progress ContinuesReturn On Capital - newsline.com
XLO News | XILIO THERAPEUTICS INC (NASDAQ:XLO) - ChartMill
Werewolf Therapeutics Stock Stalls While HOWL Holds for Strategic Update - Bez Kabli
[EFFECT] Xilio Therapeutics, Inc. SEC Filing - Stock Titan
Xilio Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline AdvancesPreliminary Results - newsline.com
Xilio Therapeutics (XLO) Holds Near Resistance as Price Action Remains Range-BoundGap Down Bounce Plays - newsline.com
Xilio Therapeutics (XLO) Shows Resilience with 1.91% Gain, Testing Key ResistanceVWAP Breakout - The Legal Advocate
Xilio Therapeutics (NASDAQ: XLO) amends shelf to include $14.5M ATM and updated exhibits - Stock Titan
XLO Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesEarnings Yield Analysis - The Legal Advocate
Is Xilio Therapeutics (XLO) Still a Buy After +2.89% Rally? 2026-05-21Wyckoff Upthrust - Newser
Xilio Therapeutics (XLO) Crushes Q1 2026 Estimates — EPS $-0.58 Tops ViewsHigh Interest Stocks - Newser
Cancer Stocks That Are Advancing the Future of Oncology Care - TradingView
Xilio Therapeutics, Inc. (XLO) reports Q1 loss, beats revenue estimates - MSN
Xilio Therapeutics (XLO) Stock Analysis: Falls -5.11%, Watching $7.94 2026-05-17Technical Analysis - Newser
Xilio Therapeutics (XLO) upgraded to buy: What does it mean for the stock? - MSN
OrbiMed group discloses stakes in Xilio Therapeutics (NASDAQ: XLO), up to 9.99% - Stock Titan
Bain Capital entities report 9.99% stake in Xilio Therapeutics (XLO) - Stock Titan
Point72 (XLO) files 13G/A showing 0% stake in Xilio Therapeutics - Stock Titan
Sirenia and Alex Silverstein report 9.9% stake in Xilio (NASDAQ: XLO) - Stock Titan
TradingKey - TradingKey
Xilio Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Xilio Therapeutics, Inc. 2026 Q1 Quarterly Report: Financials, Risk Factors, and Business Overview - Minichart
XLO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sagimet Biosciences Releases Q1 2026 Financial Results - AlphaStreet
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Xilio Therapeutics Reports Q1 2026 Financial Results, Advances Pipeline with XTX501 IND Filing and AbbVie Milestone Extension - Minichart
Xilio Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
According to documents submitted to the U.S. Securities and Exchange Commission (SEC), biotechnology company Xilio Therapeutics Inc. has entered into a common stock sales agreement with investment bank Leerink Partners LLC. - Bitget
Xilio Therapeutics (NASDAQ: XLO) files $250M shelf, includes $17.22M ATM - Stock Titan
Xilio Therapeutics, Inc. 1Q 2026: Revenue $12.6M, EPS $(0.58) — 10-Q Summary - TradingView
Xilio Therapeutics Inc (XLO) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):